Real-world study of asciminib in newly diagnosed chronic myeloid leukemia in China
Observes how asciminib works and is tolerated in adults newly diagnosed with chronic myeloid leukemia.
Plain-language title generated from the registry record
Registry title: Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China
Key facts
- Where
- Wuhan, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT07375355, who can take part
Where in China
- WuhanWuhan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT07375355
- Record updated
- 1 April 2026
- Original description
This is a multicenter, non-interventional real-world study designed to assess the efficacy and safety of asciminib in patients with newly diagnosed CML.The study uses a prospective data collection design to gather baseline, pre- and post-treatment, and long-term follow-up data, enabling a comprehensive assessment of asciminib's clinical benefits.Read full original descriptionShow less
Explore the Effectiveness and Safety of Scemblix (Asciminib) for Newly Diagnosed CML-CP Patients in China Real World Setting (ASC4CN)
This is a multicenter, non-interventional real-world study designed to assess the efficacy and safety of asciminib in patients with newly diagnosed CML.The study uses a prospective data collection design to gather baseline, pre- and post-treatment, and long-term follow-up data, enabling a comprehensive assessment of asciminib's clinical benefits.
Inclusion: Patients eligible for inclusion in this study must meet all the following criteria:; 18 years or older at the time of ICF signing; Newly diagnosed with Ph+ CML-CP within 3 months before enrollment; The diagnosis documentation must include the type and quantitative level of the BCR-ABL1 transcript; Prior treatment with a maximum of 2 weeks of TKIs; Prior treatment with non-TKI regimens, including interferon and hydroxyurea, is allowed; Patients scheduled to initiate treatment with asciminib; Patients beginning asciminib treatment must receive the first dose within 14 days of signing the ICF; Signed ICF.
Exclusion: Previous diagnosis of CML-accelerated phase or blast crisis; Concurrent other malignancies (refer to the International ICD-11 diagnosis codes, with diagnostic text including carcinoma, malignant neoplasm, etc.); Other conditions that are considered not suitable for the study by the investigator; Patients meeting any of the following criteria are not eligible for inclusion in this study:; Currently participating in an interventional clinical study for CML; Having rare, atypical transcript types that cannot be standardised internationally; Women who are pregnant, lactating or planning to become pregnant during the study.